These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34026426)

  • 1. CD38-Targeted Theranostics of Lymphoma with
    Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
    Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoPET imaging of CD38 in murine lymphoma models using
    Kang L; Jiang D; England CG; Barnhart TE; Yu B; Rosenkrans ZT; Wang R; Engle JW; Xu X; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1372-1381. PubMed ID: 29450576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Development of CD38-Targeted [
    Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
    J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
    Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
    Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Theranostic Efficacy of
    Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
    Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
    Cho N; Ko S; Shokeen M
    Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
    Yu T; Qiao C; Lv M; Tang L
    BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD38 as a PET Imaging Target in Lung Cancer.
    Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W
    Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
    Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
    Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
    J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ImmunoPET of Malignant and Normal B Cells with
    Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
    Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic effectiveness of
    Pichard A; Marcatili S; Karam J; Constanzo J; Ladjohounlou R; Courteau A; Jarlier M; Bonnefoy N; Patzke S; Stenberg V; Coopman P; Cartron G; Navarro-Teulon I; Repetto-Llamazares A; Heyerdahl H; Dahle J; Bardiès M; Pouget JP
    Leukemia; 2020 May; 34(5):1315-1328. PubMed ID: 31836849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
    Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
    J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.